NZ745725A - Oligonucleotide conjugates - Google Patents

Oligonucleotide conjugates

Info

Publication number
NZ745725A
NZ745725A NZ74572513A NZ74572513A NZ745725A NZ 745725 A NZ745725 A NZ 745725A NZ 74572513 A NZ74572513 A NZ 74572513A NZ 74572513 A NZ74572513 A NZ 74572513A NZ 745725 A NZ745725 A NZ 745725A
Authority
NZ
New Zealand
Prior art keywords
oligonucleotide conjugates
totalmer
mixmer
cleavable
oligonucleotides
Prior art date
Application number
NZ74572513A
Inventor
Nanna Albæk
Henrik Frydenlund Hansen
Susanne Kammler
Jacob Ravn
HENRIK øRUM
Original Assignee
Roche Innovation Ct Copenhagen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Innovation Ct Copenhagen As filed Critical Roche Innovation Ct Copenhagen As
Priority claimed from NZ70817113A external-priority patent/NZ708171A/en
Publication of NZ745725A publication Critical patent/NZ745725A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to the field of oligonucleotide therapeutics, and in particular to the use of a cleavable, e.g. a phosphodiester region covalently attached to a conjugate and a mixmer or totalmer, a targeting group or blocking group to enhance the properties of the oligonucleotides, for example to improve the therapeutic index.
NZ74572513A 2012-11-15 2013-11-14 Oligonucleotide conjugates NZ745725A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12192773 2012-11-15
EP13153296 2013-01-30
EP13157237 2013-02-28
EP13174092 2013-06-27
NZ70817113A NZ708171A (en) 2012-11-15 2013-11-14 Oligonucleotide conjugates

Publications (1)

Publication Number Publication Date
NZ745725A true NZ745725A (en) 2019-10-25

Family

ID=68318670

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ74178213A NZ741782A (en) 2012-11-15 2013-11-14 Oligonucleotide conjugates
NZ74572513A NZ745725A (en) 2012-11-15 2013-11-14 Oligonucleotide conjugates

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ74178213A NZ741782A (en) 2012-11-15 2013-11-14 Oligonucleotide conjugates

Country Status (1)

Country Link
NZ (2) NZ741782A (en)

Also Published As

Publication number Publication date
NZ741782A (en) 2019-10-25

Similar Documents

Publication Publication Date Title
MY173826A (en) Oligonucleotide conjugates
EP2563366A4 (en) Uses of phospholipid conjugates of synthetic tlr7 agonists
EA032986B1 (en) Pyrrolobenzodiazepines
EA032867B9 (en) Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
BR112015018161A2 (en) LNA ANTISENSE OLIGOMER CONJUGATE, PHARMACEUTICAL COMPOSITION AND USE OF AN LNA ANTISENSE OLIGOMER CONJUGATE
MX344009B (en) Amatoxin-conjugates with improved linkages.
MX2019009283A (en) PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF.
NZ706853A (en) Vegf neutralizing prodrugs for the treatment of ocular conditions
MX2012000575A (en) ε-POLYLYSINE CONJUGATES AND USE THEREOF.
MX2018013332A (en) Targeted pyrrolobenzodiazapine conjugates.
HK1206268A1 (en) Non linear multiblock copolymer drug conjugates for the delivery of active agents
MX344010B (en) Amatoxin-conjugates with improved linkers.
EA201591178A1 (en) IMPROVED COMPOSITIONS FOR EXTRACT PASSING FOR TREATING MUSCLE DISTROPHIA
EP2910573A4 (en) Antibody-drug conjugate produced by binding through linker having hydrophilic structure
MX2021003858A (en) Conjugates for treating diseases caused by psma expressing cells.
MX2010003299A (en) Micromirs.
MY178680A (en) Hydrogel prodrugs
EP2652134A4 (en) Galactose cluster-pharmacokinetic modulator targeting moiety for sirna
EP2723393A4 (en) Extracellular targeted drug conjugates
EP2796150A4 (en) Novel oligonucleotide conjugates and use thereof
PH12015500664A1 (en) Pharmaceutical combinations comprising dual angiopoietin-2/dll4 binders and anti-vegf-r agents
WO2013120038A3 (en) Morpholino targeting dux4 for treating fshd
EP2683737A4 (en) Extracellular targeted drug conjugates
EP2766051A4 (en) Porphyrin-phospholipid conjugate microbubbles and their use as contrast agents.
EP2663338A4 (en) Oligosaccharide conjugates for targeting bacteria and uses related thereto

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 NOV 2021 BY THOMSON REUTERS

Effective date: 20200926

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 NOV 2022 BY THOMSON REUTERS

Effective date: 20211002

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 NOV 2023 BY THOMSON REUTERS

Effective date: 20221003